The concomitant utilization of buprenorphine and CYP3A4 inducers can minimize the plasma concentration of buprenorphine [see CLINICAL PHARMACOLOGY], perhaps causing lessened efficacy or onset of a withdrawal syndrome in patients who have designed physical dependence to buprenorphine.Buprenorphine has long been located for being a CYP2D6 and CYP3A4